109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
不同利妥昔单抗剂量方案在原发性膜性肾病治疗中的应用：综述
Authors Yu Y , Xu R, Li Z, Wan Q
Received 31 July 2024
Accepted for publication 16 October 2024
Published 29 October 2024 Volume 2024:17 Pages 265—273
DOI https://doi.org/10.2147/IJNRD.S489455
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Pravin Singhal
摘要：原发性膜性肾病是成人原发性肾病综合征的常见病理类型之一。针对足细胞抗原（如磷脂酶A2受体等）的致病性自身抗体可导致该疾病。在接受传统免疫抑制疗法的患者人群中，出现显著不良反应的比例较高。利妥昔单抗是一种新型鼠/人嵌合单克隆抗体，能够选择性地耗竭B淋巴细胞，从而降低血液循环中致病性自身抗体的水平，诱导膜性肾病缓解。世界各地已应用多种不同的利妥昔单抗剂量方案来治疗原发性膜性肾病，但其最佳剂量方案仍未明确。本文综合回顾了迄今为止在原发性膜性肾病治疗中使用的不同剂量利妥昔单抗的相关研究。